Dasatinib is the only FDA-approved Src-Abl inhibitor, indicated for chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia in patients who have failed first-line therapy [30,31]. The gene discussed is SRC; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.